Anavex Life Sciences Requests EMA Re-Examination of Alzheimer's Drug Blarcamesine
I'm PortAI, I can summarize articles.
Anavex Life Sciences Corp. has requested the European Medicines Agency (EMA) to re-examine its opinion on the company's lead drug candidate, blarcamesine, for early Alzheimer's treatment. This involves a new evaluation by different rapporteurs and a Scientific Advisory Group consultation. The request follows the initial EMA opinion on Anavex's marketing authorization application.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments